特发性肺纤维化诊断和治疗市场 - 预测 2023-2028

特发性肺纤维化诊断和治疗市场预计到 2021 年将达到 40.35 亿美元，预测期内復合年增长率为 12.58%，到 2028 年将达到 92.49 亿美元

本研究报告根据类型和地区的各个细分市场研究了特发性肺纤维化诊断和治疗市场。 首先，市场概述详细介绍了关键驱动因素和挑战。 然后利用波特五力模型全面分析特发性肺纤维化诊断和治疗市场。 然后价值链分析确定哪些公司属于不同流程并为不同领域做出贡献。

它还提供了有关市场发展、趋势、行业政策以及影响特发性肺纤维化诊断和治疗市场的政策的深入信息。 此外，本研究分析了特发性肺纤维化诊断和治疗市场的总体监管框架，以便利益相关者更好地了解影响整体市场格局的关键因素。

特发性肺纤维化诊断和治疗市场 - 预测 2023-2028”是一份全面的更新报告。 我们向管理层和感兴趣的利益相关者提供关键市场信息，并让他们了解关键市场信息。 我们还分析了主要市场参与者的竞争格局和详细策略，并将其绘製在我们的供应商矩阵中的四个像限中：领导者、追随者、挑战者和利基市场。

内容

第一章简介

• 市场概览
• 市场定义
• 调查范围
• 市场细分
• 货币
• 先决条件
• 基准年和预测年时间表

第 2 章研究方法

• 调查数据
• 先决条件

第 3 章执行摘要

• 调查要点

第四章市场动态

• 市场驱动因素
• 市场製约因素
• 波特五力分析
• 行业价值链分析

第五章特发性肺纤维化诊断和治疗市场：按类型

• 简介
• 诊断测试
• 药理学药物
• 手术治疗

第六章特发性肺纤维化诊断和治疗市场：按地区

• 简介
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 以色列
  • 其他
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印度尼西亚
  • 泰国
  • 其他

第七章竞争格局与分析

• 主要公司及战略分析
• 新兴公司和市场盈利能力
• 合併、收购、协议与合作
• 供应商竞争力矩阵

第八章公司简介

• Roche Holding AG
• Boehringer Ingelheim
• AdAlta
• ATS Journals
• Mayo Clinic
• Medscape

The idiopathic pulmonary fibrosis diagnostic and treatment market was valued at US$4.035 billion in 2021 and is projected to expand at a CAGR of 12.58% over the forecast period to reach US$9.249 billion by 2028.

This research study examines the idiopathic pulmonary fibrosis diagnostic and treatment market based on various segments: type and geography. First, a brief overview of the market details key driving factors and challenges. Next, Porter's five forces model analyzes the idiopathic pulmonary fibrosis diagnostic and treatment market comprehensively. This is followed by industry value chain analysis which determines the companies which are part of the different processes and contributing to various sectors.

The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the idiopathic pulmonary fibrosis diagnostic and treatment market. Moreover, the research study analyzes the overall regulatory framework of the idiopathic pulmonary fibrosis diagnostic and treatment market, offering stakeholders a better understanding of the key factors influencing the overall market environment.

Idiopathic pulmonary fibrosis diagnostic and treatment market - Forecasts from 2023 to 2028 is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape and details strategies of key market players and also plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.

The scope and coverage of the idiopathic pulmonary fibrosis diagnostic and treatment market report is as below:

• Idiopathic pulmonary fibrosis diagnostic and treatment market data tables and charts
• Market outlook with sections on drivers, restraints, Porter's and industry value chain analysis
• Market assessment by type into diagnostic testing, pharmacological drugs, and surgical treatment.
• A 360° view of the demand for idiopathic pulmonary fibrosis diagnostic and treatment market solutions/services across different geographies (North America, South America, Europe, Middle East and Africa, and Asia Pacific) with further breakdown for key countries within those regions.

Different segments covered under the idiopathic pulmonary fibrosis diagnostic and treatment market report are as below:

By Type

• Diagnostic Testing
• Pharmacological Drugs
• Surgical Treatment

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Diagnostic Testing
• 5.3. Pharmacological Drugs
• 5.4. Surgical Treatment

6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET, BY GEOGRAPHY

• 6.1. Introduction
• 6.2. North America
  • 6.2.1. United States
  • 6.2.2. Canada
  • 6.2.3. Mexico
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Argentina
  • 6.3.3. Others
• 6.4. Europe
  • 6.4.1. United Kingdom
  • 6.4.2. Germany
  • 6.4.3. France
  • 6.4.4. Spain
  • 6.4.5. Others
• 6.5. The Middle East and Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. Israel
  • 6.5.4. Others
• 6.6. Asia Pacific
  • 6.6.1. Japan
  • 6.6.2. China
  • 6.6.3. India
  • 6.6.4. South Korea
  • 6.6.5. Indonesia
  • 6.6.6. Thailand
  • 6.6.7. Others

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 7.1. Major Players and Strategy Analysis
• 7.2. Emerging Players and Market Lucrativeness
• 7.3. Mergers, Acquisitions, Agreements, and Collaborations
• 7.4. Vendor Competitiveness Matrix

8. COMPANY PROFILES

• 8.1. Roche Holding AG
• 8.2. Boehringer Ingelheim
• 8.3. AdAlta
• 8.4. ATS Journals
• 8.5. Mayo Clinic
• 8.6. Medscape